Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials

Bibliographische Detailangaben

Veröffentlicht in:	American journal of hematology 2021-08, Vol.96 (8), p.E269-E272
Hauptverfasser:	Morabito, Fortunato, Tripepi, Giovanni, Del Poeta, Giovanni, Mauro, Francesca Romana, Reda, Gianluigi, Sportoletti, Paolo, Laurenti, Luca, Coscia, Marta, Herishanu, Yair, Bossio, Sabrina, Varettoni, Marzia, Murru, Roberta, Chiarenza, Annalisa, Visentin, Andrea, Condoluci, Adalgisa, Moia, Riccardo, Pietrasanta, Daniela, Loseto, Giacomo, Consoli, Ugo, Scortechini, Ilaria, Rossi, Francesca Maria, Zucchetto, Antonella, Al‐Janazreh, Hamdi, Vigna, Ernesto, Martino, Enrica Antonia, Cassin, Ramona, D′Arrigo, Graziella, Galimberti, Sara, Rago, Angela, Angeletti, Ilaria, Biagi, Annalisa, Del Giudice, Ilaria, Bomben, Riccardo, Neri, Antonino, Fronza, Gilberto, Monti, Paola, Menichini, Paola, Olivieri, Jacopo, Cutrona, Giovanna, Rossi, Davide, Cuneo, Antonio, Di Raimondo, Francesco, Gaidano, Gianluca, Polliack, Aaron, Trentin, Livio, Foà, Robin, Ferrarini, Manlio, Gattei, Valter, Gentile, Massimo
Format:	Artikel
Sprache:	eng
Schlagworte:	Chronic lymphocytic leukemia Clinical trials Hematology Immunotherapy Inhibitor drugs Lymphatic leukemia Monoclonal antibodies Rituximab Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!